FDA Approves EYLEA HD for Extended Dosing Up to 5 Months, First and Only Anti-VEGF with Widest Interval
summarizeSummary
Regeneron Pharmaceuticals announced that its EYLEA HD® (aflibercept) has received FDA approval for extended dosing intervals of up to 20 weeks (5 months) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). This makes EYLEA HD the first and only injectable anti-VEGF therapy with such extended dosing, offering a significant competitive advantage by reducing treatment burden for patients who have responded successfully after one year. The approval is based on 96-week data from the pivotal PULSAR and PHOTON trials, demonstrating sustained efficacy and safety. This regulatory milestone for a key revenue driver is expected to enhance EYLEA HD's market position and patient adherence, positively impacting Regeneron's future sales and competitive landscape. Traders will watch for market adoption and competitive responses.
At the time of this announcement, REGN was trading at $747.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.6B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.